Sermorelin
Testides
Batch SERM-CA-26D-01
Sermorelin
GHRH(1-29) Analogue
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth-hormone-releasing hormone, studied in research on the GH/IGF-1 axis.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth-hormone-releasing hormone, studied in research on the GH/IGF-1 axis.
Experimental models examine GHRH-receptor stimulation and downstream secretory dynamics under controlled conditions.
Third-party tested for purity, ID, quantity.
Sermorelin (GHRH 1-29) is the shortest fully active fragment of growth-hormone-releasing hormone, characterized in research for its ability to stimulate physiologic growth-hormone release. Investigations have examined GHRH-receptor pharmacology and GH-secretory dynamics.
Studies span endocrine-axis and neuroendocrine research frameworks under structured conditions.
Sermorelin was developed from the characterization of growth-hormone-releasing hormone and the identification of its minimal active sequence.
Research has since used it as a reference GHRH analogue in studies of the GH/IGF-1 axis.
Research into sermorelin focuses on GHRH-receptor signaling and GH/IGF-1 axis regulation. Frameworks evaluate secretagogue pharmacology and secretory dynamics under controlled conditions.
0 of the 4 areas below are addressed directly by a paper cited on this page.
GHRH-receptor activation models
No paper cited on this page reports on ghrh, receptor or activation. This heading marks where Sermorelin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
GH/IGF-1 axis regulation research
No paper cited on this page reports on axis or regulation. This heading marks where Sermorelin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Neuroendocrine signaling studies
No paper cited on this page reports on neuroendocrine. This heading marks where Sermorelin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Secretory-dynamics endpoint investigations
No paper cited on this page reports on secretory, dynamics or endpoint. This heading marks where Sermorelin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 1986 and 2021 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Sermorelin, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Sermorelin is also referred to as GRF 1-29.
Sermorelin is commonly described online in connection with muscle growth, fat loss and improved recovery. In the research literature the same compound is filed under GHRH-receptor activation models, GH/IGF-1 axis regulation research and neuroendocrine signaling studies.
The 3 papers cited on this page, published between 1986 and 2021 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Sermorelin is per lot, not per product. The current lot SERM-CA-26D-01 returned 98.78% purity, 5.56 mg measured, assayed by Testides. Those figures are the laboratory's, published in full rather than reduced to a badge.
The lot code printed on the vial matches the code on the certificate for Sermorelin. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Sermorelin in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Sermorelin is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 29 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (5mg / Single Vial, 5mg / 5-Pack, 5mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of sermorelin. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99